Pharnext S.C.A. (P0X.F)

0.0259 -0.0317 (-55.03%) At close: 08:18AM CEST

Pharnext S.C.A.

14 rue de la République
Suresnes 92150
France

https://pharnext.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 23

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Daniel E. Cohen M.D., Ph.D.	Director	319.3k	N/A	1953
Mr. Hugo Brugiere M.Sc.	CEO & Chairman	N/A	N/A	N/A
Mr. Ilya Chumakov D-Sc, Ph.D.	Co-Founder, Chairman of Scientific Advisory Board and Director	N/A	N/A	N/A
Mr. Vincent Serra Ph.D.	COO & Chief Scientific Officer	N/A	N/A	1970
Mr. Abhijit Pangu	Head of Regulatory Affairs	N/A	N/A	N/A
Mr. Raj Thota M.Sc.	Chief Manufacturing Officer & Head of CMC	N/A	N/A	N/A
Mr. Scott Johnson B.Sc.	VP & Head of Quality	N/A	N/A	N/A
Mr. Gilbert Wagener M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2016, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.

Corporate governance

Pharnext S.C.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.